Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

  • Post published:September 19, 2022
  • Post category:Press Release
Read more about the article Numinus provides update on acquisition integration and announces new client financing options

Numinus provides update on acquisition integration and announces new client financing options

  • Post published:September 13, 2022
  • Post category:Press Release
Read more about the article Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

  • Post published:August 31, 2022
  • Post category:Press Release
Read more about the article Numinus Wellness Inc. Reports Q3 2022 Results

Numinus Wellness Inc. Reports Q3 2022 Results

  • Post published:July 16, 2022
  • Post category:Press Release
Read more about the article Numinus to Host Q3 2022 Results Conference Call on July 14, 2022

Numinus to Host Q3 2022 Results Conference Call on July 14, 2022

  • Post published:July 7, 2022
  • Post category:Press Release
Read more about the article Numinus Unveils New Logo and Brand Identity

Numinus Unveils New Logo and Brand Identity

  • Post published:June 28, 2022
  • Post category:Press Release
Read more about the article Numinus Applies for International Patent Filing of Psychedelics Production Process

Numinus Applies for International Patent Filing of Psychedelics Production Process

  • Post published:June 22, 2022
  • Post category:Press Release
Read more about the article Numinus Wellness Inc. Reports Q2 2022 Results

Numinus Wellness Inc. Reports Q2 2022 Results

  • Post published:April 14, 2022
  • Post category:Press Release
Read more about the article Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research

Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research

  • Post published:April 12, 2022
  • Post category:Press Release
Read more about the article Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

  • Post published:March 30, 2022
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More